Safety Study of Chinese Herbal Therapy to Treat Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Anti-Asthma Herbal Medical Intervention (ASHMI)
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Chinese Herbal Therapy, Asthma, Investigational new drug (IND), Complementary and Alternative Medicine
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects ages 18-40 and otherwise in good health as determined by medical history and physical examination
- History of asthma documented by a physician
- Documentation of allergy to two or more common environmental allergens as evidenced by positive prick skin or RAST testing
- The subject agrees to participate in the study
- Females of childbearing potential must be inactive sexually or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study.
Exclusion Criteria:
- Acute illness (such as cold, flu, etc.) within one week before the administration of study drug
- Any history of systemic disease that in the investigator's opinion would preclude the subject from participating in this study, including viral hepatitis infection (by patient self-report)
- Abnormal hepatic function
- Abnormal bone marrow function
- Abnormal renal function
- Clinically significant abnormal electrocardiogram
- Current uncontrolled moderate to severe asthma with FEV1 <80% predicted
- Participation in another experimental study within 30 days of this study
- History of alcohol or drug abuse (by self report)
- Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test to be considered for this study
- Current smokers
Sites / Locations
- Mount Sinai School Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
Arm Label
1a
1b
2a
2b
3a
3b
Arm Description
Low dose ASHMI (2 caps bid).
Placebo 2 caps bid.
Medium dose ASHMI (4 caps bid).
Placebo 4 caps bid.
High dose ASHMI (6 caps bid).
Placebo 6 caps bid.
Outcomes
Primary Outcome Measures
Drug safety (absence of severe adverse effects)
Secondary Outcome Measures
Clinically significant changes in electrocardiogram
Clinically significant changes in blood count
Clinically significant changes in serum chemistries
Clinically significant changes in renal function
Clinically significant changes in liver function
Clinically significant changes in urinalysis
Allergen-specific IgE levels
Total IgA level
T-cell cytokine profile
Prostaglandin levels
Full Information
NCT ID
NCT00601263
First Posted
January 15, 2008
Last Updated
January 18, 2018
Sponsor
Xiu-Min Li
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
1. Study Identification
Unique Protocol Identification Number
NCT00601263
Brief Title
Safety Study of Chinese Herbal Therapy to Treat Asthma
Official Title
Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase I
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
July 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xiu-Min Li
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the safety of an anti-asthma herbal medicine intervention (ASHMI) in adult asthmatics and to see what effects ASHMI has on certain parts of the immune system.
Detailed Description
Asthma is a major public health problem worldwide, particularly in westernized societies and has continued to increase in prevalence over the past two decades. Inhaled corticosteroids have become the first-line treatment for persistent asthma even though significant side effects have been reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown only marginal benefits. Patients have increasingly turned to complementary and alternative medicine (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of well-controlled scientific studies.
We have developed a Chinese herbal formula composed of 3 herbs called ASHMI. It has been previously shown in murine studies that ASHMI (a formula containing Ling Zhi, Ku Shen and Gan Cao) has therapeutic effects on the major pathogenic mechanisms of asthma-airway hyperreactivity, pulmonary inflammation, and airway remodeling, as well as a down-regulating of TH2 response. A subsequent study in 91 asthmatic patients in Weifang, China found ASHMI to be a safe and effective alternative to prednisone for treating asthma and exhibited a beneficial effect on TH1 and TH2 balance. Based on these preliminary studies, we hypothesize that ASHMI will be a safe medication in atopic patients with asthma and will lead to identifiable changes in serum immunologic markers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Chinese Herbal Therapy, Asthma, Investigational new drug (IND), Complementary and Alternative Medicine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1a
Arm Type
Active Comparator
Arm Description
Low dose ASHMI (2 caps bid).
Arm Title
1b
Arm Type
Placebo Comparator
Arm Description
Placebo 2 caps bid.
Arm Title
2a
Arm Type
Active Comparator
Arm Description
Medium dose ASHMI (4 caps bid).
Arm Title
2b
Arm Type
Placebo Comparator
Arm Description
Placebo 4 caps bid.
Arm Title
3a
Arm Type
Active Comparator
Arm Description
High dose ASHMI (6 caps bid).
Arm Title
3b
Arm Type
Placebo Comparator
Arm Description
Placebo 6 caps bid.
Intervention Type
Drug
Intervention Name(s)
Anti-Asthma Herbal Medical Intervention (ASHMI)
Intervention Description
We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
Primary Outcome Measure Information:
Title
Drug safety (absence of severe adverse effects)
Time Frame
1 week
Secondary Outcome Measure Information:
Title
Clinically significant changes in electrocardiogram
Time Frame
1 week
Title
Clinically significant changes in blood count
Time Frame
1 week
Title
Clinically significant changes in serum chemistries
Time Frame
1 week
Title
Clinically significant changes in renal function
Time Frame
1 week
Title
Clinically significant changes in liver function
Time Frame
1 week
Title
Clinically significant changes in urinalysis
Time Frame
1 week
Title
Allergen-specific IgE levels
Time Frame
1 week
Title
Total IgA level
Time Frame
1 week
Title
T-cell cytokine profile
Time Frame
1 week
Title
Prostaglandin levels
Time Frame
1 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female subjects ages 18-40 and otherwise in good health as determined by medical history and physical examination
History of asthma documented by a physician
Documentation of allergy to two or more common environmental allergens as evidenced by positive prick skin or RAST testing
The subject agrees to participate in the study
Females of childbearing potential must be inactive sexually or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study.
Exclusion Criteria:
Acute illness (such as cold, flu, etc.) within one week before the administration of study drug
Any history of systemic disease that in the investigator's opinion would preclude the subject from participating in this study, including viral hepatitis infection (by patient self-report)
Abnormal hepatic function
Abnormal bone marrow function
Abnormal renal function
Clinically significant abnormal electrocardiogram
Current uncontrolled moderate to severe asthma with FEV1 <80% predicted
Participation in another experimental study within 30 days of this study
History of alcohol or drug abuse (by self report)
Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test to be considered for this study
Current smokers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Wisnivesky, MD, MPH
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai School Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
16159618
Citation
Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, Mu DZ, Du JB, Li GH, Wallenstein S, Sampson H, Kattan M, Li XM. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 2005 Sep;116(3):517-24. doi: 10.1016/j.jaci.2005.05.029.
Results Reference
background
Learn more about this trial
Safety Study of Chinese Herbal Therapy to Treat Asthma
We'll reach out to this number within 24 hrs